Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

  • ID: 3972706
  • Drug Pipelines
  • 266 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • ImmunoGen, Inc.
  • Innate Pharma S.A.
  • MorphoSys AG
  • MORE
Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016

The latest Pharmaceutical and Healthcare disease pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides an overview of the Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline landscape.

Leukemia that does not responded to treatment is called refractory chronic lymphocytic leukemia. Symptoms include fever and infection, abnormal bleeding, shortness of breath, weight loss and swelling of lymph nodes. Treatment includes stem cell transplantation or bone marrow transplantation.

Report Highlights:

The Pharmaceutical and Healthcare latest pipeline guide Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Refractory Chronic Lymphocytic Leukemia (CLL) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I and Preclinical stages are 1, 4, 21, 16 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.Refractory Chronic Lymphocytic Leukemia (CLL).

Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology)

Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Refractory Chronic Lymphocytic Leukemia (CLL) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 4SC AG
  • Astellas Pharma Inc.
  • Celgene Corporation
  • ImmunoGen, Inc.
  • Innate Pharma S.A.
  • MorphoSys AG
  • MORE
Introduction

Refractory Chronic Lymphocytic Leukemia (CLL) Overview

Therapeutics Development

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Overview

Pipeline Products for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Development by Companies

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics under Investigation by Universities/Institutes

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Development by Companies

Refractory Chronic Lymphocytic Leukemia (CLL) - Products under Investigation by Universities/Institutes

Refractory Chronic Lymphocytic Leukemia (CLL) - Companies Involved in Therapeutics Development

4SC AG

AbbVie Inc

Arno Therapeutics, Inc.

Astellas Pharma Inc.

Astex Pharmaceuticals Inc

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Celgene Corporation

Cellular Biomedicine Group, Inc.

F. Hoffmann-La Roche Ltd.

Gilead Sciences, Inc.

Hutchison MediPharma Limited

ImmunoGen, Inc.

Immunomedics, Inc.

Incyte Corporation

Innate Pharma S.A.

Juno Therapeutics Inc.

Karyopharm Therapeutics, Inc.

LFB S.A.

Lymphocyte Activation Technologies, S.A.

Medicenna Therapeutics, Inc.

Millennium Pharmaceuticals Inc

MorphoSys AG

Novartis AG

Oncternal Therapeutics, Inc.

Ono Pharmaceutical Co., Ltd.

Portola Pharmaceuticals, Inc.

Sanofi

Tragara Pharmaceuticals, Inc.

Verastem, Inc.

Refractory Chronic Lymphocytic Leukemia (CLL) - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Combination Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

(dezapelisib + itacitinib adipate) - Drug Profile

4SC-202 - Drug Profile

acalabrutinib - Drug Profile

ACP-319 - Drug Profile

afuresertib hydrochloride - Drug Profile

AGS-67E - Drug Profile

AR-42 - Drug Profile

AT-7519 - Drug Profile

atezolizumab - Drug Profile

BI-836826 - Drug Profile

BMS-986016 - Drug Profile

buparlisib hydrochloride - Drug Profile

CBM-C19.1 - Drug Profile

CBM-C20.1 - Drug Profile

CC-122 - Drug Profile

Cellular Immunotherapy for Chronic Lymphocytic Leukaemia - Drug Profile

Cellular Immunotherapy to Target Receptor Tyrosine Kinase-Like Orphan Receptor 1 for Chronic Lymphocytic Leukemia - Drug Profile

cerdulatinib - Drug Profile

duvelisib - Drug Profile

HMPL-523 - Drug Profile

idelalisib - Drug Profile

IMGN-529 - Drug Profile

IMMU-114 - Drug Profile

JCAR-014 - Drug Profile

JCAR-015 - Drug Profile

lirilumab - Drug Profile

MDNA-56 - Drug Profile

monalizumab - Drug Profile

MOR-208 - Drug Profile

nivolumab - Drug Profile

obinutuzumab - Drug Profile

PCAR-019 - Drug Profile

PCAR-119 - Drug Profile

pilaralisib - Drug Profile

S-055746 - Drug Profile

selinexor - Drug Profile

spebrutinib besylate - Drug Profile

TAK-659 - Drug Profile

TG-02 - Drug Profile

tisagenlecleucel-T - Drug Profile

ublituximab - Drug Profile

UC-961 - Drug Profile

ulocuplumab - Drug Profile

urelumab - Drug Profile

venetoclax - Drug Profile

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products

Refractory Chronic Lymphocytic Leukemia (CLL) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Number of Products under Development by Companies, H2 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Comparative Analysis by Early Stage Development, H2 2016

Products under Development by Companies, H2 2016

Products under Development by Companies, H2 2016 (Contd..1)

Products under Development by Companies, H2 2016 (Contd..2)

Products under Investigation by Universities/Institutes, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by 4SC AG, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by AbbVie Inc, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Arno Therapeutics, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astellas Pharma Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Astex Pharmaceuticals Inc, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Boehringer Ingelheim GmbH, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Bristol-Myers Squibb Company, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Celgene Corporation, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Cellular Biomedicine Group, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Gilead Sciences, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Hutchison MediPharma Limited, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by ImmunoGen, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Immunomedics, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Incyte Corporation, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Innate Pharma S.A., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Juno Therapeutics Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Karyopharm Therapeutics, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by LFB S.A., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Lymphocyte Activation Technologies, S.A., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Medicenna Therapeutics, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Millennium Pharmaceuticals Inc, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by MorphoSys AG, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Novartis AG, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Oncternal Therapeutics, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Portola Pharmaceuticals, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Sanofi, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Tragara Pharmaceuticals, Inc., H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Pipeline by Verastem, Inc., H2 2016

Assessment by Monotherapy Products, H2 2016

Assessment by Combination Products, H2 2016

Number of Products by Stage and Target, H2 2016

Number of Products by Stage and Mechanism of Action, H2 2016

Number of Products by Stage and Route of Administration, H2 2016

Number of Products by Stage and Molecule Type, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects, H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Dormant Projects (Contd..1), H2 2016

Refractory Chronic Lymphocytic Leukemia (CLL) - Discontinued Products, H2 2016

List of Figures

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL), H2 2016

Number of Products under Development for Refractory Chronic Lymphocytic Leukemia (CLL) - Comparative Analysis, H2 2016

Number of Products under Development by Companies, H2 2016

Comparative Analysis by Late Stage Development, H2 2016

Comparative Analysis by Clinical Stage Development, H2 2016

Assessment by Monotherapy Products, H2 2016

Number of Products by Top 10 Targets, H2 2016

Number of Products by Stage and Top 10 Targets, H2 2016

Number of Products by Top 10 Mechanism of Actions, H2 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016

Number of Products by Routes of Administration, H2 2016

Number of Products by Stage and Routes of Administration, H2 2016

Number of Products by Molecule Types, H2 2016

Number of Products by Stage and Molecule Types, H2 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 4SC AG
  • AbbVie Inc
  • Arno Therapeutics, Inc.
  • Astellas Pharma Inc.
  • Astex Pharmaceuticals Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Celgene Corporation
  • Cellular Biomedicine Group, Inc.
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Hutchison MediPharma Limited
  • ImmunoGen, Inc.
  • Immunomedics, Inc.
  • Incyte Corporation
  • Innate Pharma S.A.
  • Juno Therapeutics Inc.
  • Karyopharm Therapeutics, Inc.
  • LFB S.A.
  • Lymphocyte Activation Technologies, S.A.
  • Medicenna Therapeutics, Inc.
  • Millennium Pharmaceuticals Inc
  • MorphoSys AG
  • Novartis AG
  • Oncternal Therapeutics, Inc.
  • Ono Pharmaceutical Co., Ltd.
  • Portola Pharmaceuticals, Inc.
  • Sanofi
  • Tragara Pharmaceuticals, Inc.
  • Verastem, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll